According to the report, The global Suramin Sodium market in 2019 was approximately USD XXX Million. The market is expected to grow above a CAGR of XX% and is anticipated to reach over USD XXX Million by 2026.
Suramine is used to treat sleeping sickness in humans with trypanosoma. This is mainly used to treat early-African trypanosomiasis caused by the Trypanosoma brucei rhodesian and Trypanosoma brucei gambiense central nervous system. Trypanosoma brucei rhodesiense is considered the main line therapy and secondary line therapy for trypanosoma brucei gambiense, in which first line pentamidine is prescribed.
Request to Access Free Sample, Click HERE
Suramine is not mouth biodisponible and is administered intravenously. The intramuscular and subcutaneous administration of local tissue may be caused by inflammation or necrosis. Suramine has an average half-life time of 41-78 days for 50 days, while suramine pharmacokinetics vary significantly among individual patients and are about 99-98 percent serum protein bound. Suramine does not quickly spread to the cerebral fluid and the concentration of its tissues is less than its plasma level. Suramine is not easily metabolized and about 80 percent are excreted into the kidneys.
Suramine is identified by the drugs of low-density lipoproteins, and in lesser measure by other serum protéins, via receptor-mediated endocytosis. Suramine Suramine inhibits energy metabolism once combined with proteins in parasites, especially trypanosomal glycolytic enzymes.The Suramin Sodium market is segmented based on drug type and region. On the basis of drug type segmentation, the market is classified into antidepressant drugs, mood stabilizers, antipsychotics drugs, and others.
To Make An Inquiry About This Report, Click HERE
Some of the essential players operating in the Suramin Sodium market, but not restricted to include Glaxo SmithKline (GSK), Eli Lilly, AstraZeneca, Pfizer Inc., Janssen Pharmaceuticals, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company Allergan Plc., Otsuka Holdings Co. Ltd., and Others.
Facts & Factors
USA: 1 (347) 690-0211
Email: [email protected]